Contact
searchSearch
HMP Global
Login

Follicular Lymphoma Specialty Channel

Follicular Lymphoma
Specialty Channel
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
FDA Approval
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
06/18/2025
Emily Estrada
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab...
06/18/2025
Oncology
Conference Coverage
Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma
06/06/2025
Emily Estrada
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated...
06/06/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL
06/04/2025
Emily Estrada
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2...
06/04/2025
Oncology
Conference Coverage
Tazemetostat for Relapsed/Refractory FL and DLBCL
06/04/2025
Emily Estrada
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates...
06/04/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Lisocabtagene Maraleucel Demonstrates Potential Improved Efficacy Over Mosunetuzumab for Third-Line or Later Treatment of R/R Follicular Lymphoma
03/25/2025
Emily Estrada
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel...
03/25/2025
Oncology
Christina Poh, MD
Videos
Tafasitamab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
01/15/2025
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to...
01/15/2025
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
Amber Denham
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology

News

FDA Approval
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
06/18/2025
Emily Estrada
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab...
06/18/2025
Oncology
Conference Coverage
Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma
06/06/2025
Emily Estrada
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated...
06/06/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL
06/04/2025
Emily Estrada
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2...
06/04/2025
Oncology
Conference Coverage
Tazemetostat for Relapsed/Refractory FL and DLBCL
06/04/2025
Emily Estrada
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates...
06/04/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Lisocabtagene Maraleucel Demonstrates Potential Improved Efficacy Over Mosunetuzumab for Third-Line or Later Treatment of R/R Follicular Lymphoma
03/25/2025
Emily Estrada
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel...
03/25/2025
Oncology
Christina Poh, MD
Videos
Tafasitamab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
01/15/2025
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to...
01/15/2025
Oncology
News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
Amber Denham
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology

Interactive Features

Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
Quiz
Predictive Value of Ki67 Expression for Follicular Lymphoma
08/03/2023
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study...
08/03/2023
Oncology
Quiz
Subcutaneous Rituximab for Low-Tumor Burden FL
06/07/2023
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study...
06/07/2023
Oncology
Quiz
EZH2 Inhibitor PF-06821497 for Follicular Lymphoma
05/30/2023
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study...
05/30/2023
Oncology
Quiz
Quiz: Linperlisib for R/R Follicular Lymphoma
04/25/2023
A study assessing the efficacy and safety of linperlisib for the treatment of relapsed/refractory follicular lymphoma found that patients who received this oral PI3Kδ inhibitor reached an overall response rate of ___.
A study assessing the efficacy and safety of linperlisib for the treatment of relapsed/refractory follicular lymphoma found that patients who received this oral PI3Kδ inhibitor reached an overall response rate of ___.
A study assessing the efficacy...
04/25/2023
Oncology
Quiz
Quiz: Odronextamab Plus Optimized Step-Up Regimen for Follicular Lymphoma
03/31/2023
Patients with R/R follicular lymphoma grade 1 to 3a who received odronextamab plus an optimized step-up regimen reached an overall response of ___.
Patients with R/R follicular lymphoma grade 1 to 3a who received odronextamab plus an optimized step-up regimen reached an overall response of ___.
Patients with R/R follicular...
03/31/2023
Oncology

Recent News

FDA Approval
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
06/18/2025
Emily Estrada
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab...
06/18/2025
Oncology
Conference Coverage
Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma
06/06/2025
Emily Estrada
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated...
06/06/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL
06/04/2025
Emily Estrada
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2...
06/04/2025
Oncology
Conference Coverage
Tazemetostat for Relapsed/Refractory FL and DLBCL
06/04/2025
Emily Estrada
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates promising clinical activity and tolerability for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma who have undergone at least 2 lines of prior therapy.
Tazemetostat demonstrates...
06/04/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Lisocabtagene Maraleucel Demonstrates Potential Improved Efficacy Over Mosunetuzumab for Third-Line or Later Treatment of R/R Follicular Lymphoma
03/25/2025
Emily Estrada
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel...
03/25/2025
Oncology
News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
Amber Denham
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use